Team is first in Texas to join NIH-sponsored hospital study investigating efficacy of convalescent plasma for COVID-19

August 27, 2020

Plasma, shown here in an IV bag, will be used for a randomized trial at UTHealth. (Photo by Getty Images)
Using a multimillion-dollar grant from the National Institutes of Health, physician-scientists at The University of Texas Health Science Center at Houston (UTHealth) will investigate whether convalescent plasma infusions can prevent the progression of COVID-19 in one of the first randomized clinical trials in the country.

As part of the Center for Clinical and Translational Sciences, UTHealth and The University of Texas Health Science Center at Tyler are joining a study established by New York University (NYU) and Montefiore Medical Center/Albert Einstein College of Medicine to evaluate the safety and efficacy of convalescent plasma in hospitalized coronavirus patients. The trial, which will enroll patients locally at Memorial Hermann-Texas Medical Center, is funded with an $8 million grant (3UL1TR003167-02S1) from the National Center for Advancing Translational Sciences, part of the NIH.

Read the full story…

Written by: Amy Laukka  –  August 18, 2020

Share content